Ep214: Shana Kelley on a Wearable Continuous Immune Monitor
Episode
47 min
Read time
2 min
Topics
Productivity, Relationships, Startups
AI-Generated Summary
Key Takeaways
- ✓Active Reset Mechanism: The core technical breakthrough enabling continuous protein sensing uses oscillating electric fields to physically dislodge bound proteins from electrode surfaces, resetting sensors back to baseline. Without this, standard affinity-based sensors remain locked to proteins for roughly 24 hours, making real-time fluctuation tracking impossible. This "active reset" approach is now being adapted by other research groups using constant-field variations.
- ✓Interstitial Fluid Targeting: The device uses a single microneedle embedded just beneath the skin to sample interstitial fluid rather than blood, deliberately mirroring the continuous glucose monitor form factor. Smaller cytokine proteins equilibrate rapidly from blood into interstitial fluid, making them detectable at measurable concentrations without invasive blood draws, which also reduces infection risk and improves patient tolerance.
- ✓Commercialization Sequencing: Based on prior startup experience, Kelley identifies a clear sequencing requirement: academic labs must build an FDA-grade prototype before larger industrial partners will engage seriously. Early-stage hardware integration — electrical engineering, microfabrication, industrial design, sensor chemistry — is too granular for large companies, making an initial startup vehicle the practical commercialization path before any acquisition or licensing deal.
- ✓Inflammation as a Universal Clinical Signal: A review co-authored with cardiologists, neurologists, and critical care specialists identified continuous inflammatory monitoring as actionable across multiple disease areas. Heart failure patients who cycle repeatedly through hospitalization represent one near-term target, where real-time cytokine panels could enable precise medication titration and intervention timing rather than reactive crisis management after symptoms escalate.
- ✓Molecular Dynamic Simulation as a Design Tool: Partnering with a Northwestern computational chemistry group to run molecular dynamic simulations of electrode-surface sensors transformed sensor development from empirical trial-and-error into a controllable design process. Visualizing exactly how sensors behave at the electrode surface revealed previously hidden mechanisms, producing multiple "unlock moments" that accelerated optimization of sensor architecture and performance.
What It Covers
Northwestern University professor Shana Kelley describes her team's development of a continuous wearable immune monitor, modeled after continuous glucose monitors, that tracks inflammatory protein levels in real time. Mouse trials published in Science in December 2024 demonstrated proof of concept, with human clinical trials and commercialization partnerships now in active pursuit.
Key Questions Answered
- •Active Reset Mechanism: The core technical breakthrough enabling continuous protein sensing uses oscillating electric fields to physically dislodge bound proteins from electrode surfaces, resetting sensors back to baseline. Without this, standard affinity-based sensors remain locked to proteins for roughly 24 hours, making real-time fluctuation tracking impossible. This "active reset" approach is now being adapted by other research groups using constant-field variations.
- •Interstitial Fluid Targeting: The device uses a single microneedle embedded just beneath the skin to sample interstitial fluid rather than blood, deliberately mirroring the continuous glucose monitor form factor. Smaller cytokine proteins equilibrate rapidly from blood into interstitial fluid, making them detectable at measurable concentrations without invasive blood draws, which also reduces infection risk and improves patient tolerance.
- •Commercialization Sequencing: Based on prior startup experience, Kelley identifies a clear sequencing requirement: academic labs must build an FDA-grade prototype before larger industrial partners will engage seriously. Early-stage hardware integration — electrical engineering, microfabrication, industrial design, sensor chemistry — is too granular for large companies, making an initial startup vehicle the practical commercialization path before any acquisition or licensing deal.
- •Inflammation as a Universal Clinical Signal: A review co-authored with cardiologists, neurologists, and critical care specialists identified continuous inflammatory monitoring as actionable across multiple disease areas. Heart failure patients who cycle repeatedly through hospitalization represent one near-term target, where real-time cytokine panels could enable precise medication titration and intervention timing rather than reactive crisis management after symptoms escalate.
- •Molecular Dynamic Simulation as a Design Tool: Partnering with a Northwestern computational chemistry group to run molecular dynamic simulations of electrode-surface sensors transformed sensor development from empirical trial-and-error into a controllable design process. Visualizing exactly how sensors behave at the electrode surface revealed previously hidden mechanisms, producing multiple "unlock moments" that accelerated optimization of sensor architecture and performance.
Notable Moment
Kelley describes implanting sensors in diabetic rats and detecting a brief, transient cytokine spike caused solely by the needle insertion itself — a minute-level inflammatory signal that vanished quickly. This incidental finding illustrated the resolution the device achieves, capturing immune responses invisible to any existing clinical measurement tool.
Episode Transcript
Welcome to the Long Run. This is a podcast for biotech adventurers. I'm your host, Luke Timmerman. Today's guest is Shana Kelley. Shana is a professor of chemistry at Northwestern University and the president of the Chan Zuckerberg Biohub in Chicago. One of the cool projects she oversees is for a continuous wearable immune monitor. It's inspired by continuous glucose monitors that have changed the way diabetes is treated and managed. No such device exists today for the continuous tracking of inflammation. But if her team of chemists, biologists, and engineers can pull this off, it would have big implications for research and treatment of immune disorders that affect millions of more people. The detection of inflammatory proteins was demonstrated in mice and published in Science in December 2024. You can find a link to that research article in the show summary on timmermanreport.com. The next steps to build something suitable for the marketplace will require some kind of industry partnership. Shaina, like a lot of scientists, has taken a circuitous path. I enjoyed hearing her story of how she got to this moment of possibility to seize on new technology tools and growing knowledge of biology to spearhead a project with this much potential for human health. Now before we get started, a word from the sponsor of the show, AlphaSense. Anyone who's tried to stay current on a fast moving therapeutic area knows the real problem isn't finding information. It's that there's too much of it, and it changes every week. Alfasense just launched SuperAnalyst, an always on agent that works like a power user inside the platform on your behalf. It draws on Alfasense's full life sciences content universe: clinical trial data, peer reviewed literature, regulatory filings, conference presentations, and expert transcripts with researchers, clinicians, and executives. And it keeps monitoring your space even after you've closed your laptop. It's designed to act like an extension of your research team. It remembers the programs and competitors you're tracking, follows your process, and applies it automatically to new data as it comes in. And every output links back to its original source, so when you're citing a trial result, you can see exactly where the number came from. Take the task you've been meaning to get to, tracking a competitor's trial program or flagging the next regulatory decision before it hits, and hand it to SuperAnalyst. Start your free trial at alphasense.comthelongrun. All one word. That's alpha-sense.com/thelongrun. And quick question. When was the last time a CRO told you what something costs before you sign an NDA, sat through two scoping calls, and waited a week for a scope of work? In bioanalysis, pricing gets treated like a closely guarded secret. DashBio thinks that's backward. It publishes pricing publicly on its website and even has a calculator that shows how the price changes if you redesign your study. You can see what your study costs before you talk to a human being. No surprise line items. No it …
Get the full transcript (7,484 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 44-minute episode.
Get The Long Run with Luke Timmerman summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from The Long Run with Luke Timmerman
Ep213: Daphne Koller on The Moment in AI Drug Discovery
Nov 3 · 64 min
Latent Space
Extreme Harness Engineering for Token Billionaires: 1M LOC, 1B toks/day, 0% human code, 0% human review — Ryan Lopopolo, OpenAI Frontier & Symphony
Apr 7
More from The Long Run with Luke Timmerman
Ep212: Tim Shannon on Creating Targeted Protein Degraders as Medicines
Oct 23 · 74 min
Lenny's Podcast
Meta’s Muse: How we launched the most successful consumer product this year | Mona Sarantakos
Nov 15
More from The Long Run with Luke Timmerman
We summarize every new episode. Want them in your inbox?
Ep213: Daphne Koller on The Moment in AI Drug Discovery
Ep212: Tim Shannon on Creating Targeted Protein Degraders as Medicines
Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience
Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders
Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets
Similar Episodes
Related episodes from other podcasts
Latent Space
Apr 7
Extreme Harness Engineering for Token Billionaires: 1M LOC, 1B toks/day, 0% human code, 0% human review — Ryan Lopopolo, OpenAI Frontier & Symphony
Lenny's Podcast
Nov 15
Meta’s Muse: How we launched the most successful consumer product this year | Mona Sarantakos
20VC (20 Minute VC)
Nov 7
20VC: From $8BN to $19BN: Inside WashU's Endowment Fund | SpaceX Made Up 20% of Our AUM | Why Europe and China Has So Much Opportunity | The Reckoning That is Coming for AI Companies with Scott Wilson
The Vergecast
Oct 19
Why your favorite creator is building an app
David Senra
Oct 11
Creating Muse: The Fastest-Growing AI Product Since ChatGPT | Alexandr Wang, Meta
Explore Related Topics
This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Startups & Product Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into The Long Run with Luke Timmerman.
Every Monday, we deliver AI summaries of the latest episodes from The Long Run with Luke Timmerman and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime